MediWound Ltd. (MDWD) and Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) Comparison side by side

This is therefore a contrasting of the risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation in MediWound Ltd. (NASDAQ:MDWD) and Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE). The two are both Biotechnology companies that compete with one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MediWound Ltd. 3.34M 30.74 5.27M -0.21 0.00
Zynerba Pharmaceuticals Inc. N/A 3191.35 36.75M -2.27 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 has MediWound Ltd. and Zynerba Pharmaceuticals Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
MediWound Ltd. -157.78% -31.9% -2.9%
Zynerba Pharmaceuticals Inc. 0.00% -64.1% -54.9%

Risk & Volatility

MediWound Ltd. has a 0.73 beta, while its volatility is 27.00% which is less volatile than Standard and Poor’s 500. Competitively, Zynerba Pharmaceuticals Inc. is 456.00% more volatile than Standard and Poor’s 500, because of the 5.56 beta.

Liquidity

MediWound Ltd.’s Current Ratio and Quick Ratio are 6.7 and 6.3 respectively. The Current Ratio and Quick Ratio of its competitor Zynerba Pharmaceuticals Inc. are 9.9 and 9.9 respectively. Zynerba Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to MediWound Ltd.

Analyst Ratings

The next table highlights the shown recommendations and ratings for MediWound Ltd. and Zynerba Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
MediWound Ltd. 0 0 3 3.00
Zynerba Pharmaceuticals Inc. 0 0 1 3.00

$11.67 is MediWound Ltd.’s consensus price target while its potential upside is 208.73%. Meanwhile, Zynerba Pharmaceuticals Inc.’s consensus price target is $18, while its potential upside is 38.14%. The data from earlier shows that analysts view suggest that MediWound Ltd. seems more appealing than Zynerba Pharmaceuticals Inc.

Insider and Institutional Ownership

Institutional investors held 36.4% of MediWound Ltd. shares and 13.7% of Zynerba Pharmaceuticals Inc. shares. About 41.5% of MediWound Ltd.’s share are held by insiders. Competitively, Zynerba Pharmaceuticals Inc. has 0.9% of it’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
MediWound Ltd. -7.45% -6.05% -6.25% -23.01% -29.84% 7.14%
Zynerba Pharmaceuticals Inc. 13.82% 66.71% 156.35% 133.95% 47.46% 368.69%

For the past year MediWound Ltd. was less bullish than Zynerba Pharmaceuticals Inc.

Summary

MediWound Ltd. beats on 6 of the 10 factors Zynerba Pharmaceuticals Inc.

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products in Israel. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Zynerba Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates include ZYN002, which is in Phase II clinical trial for adult patients with refractory epileptic focal seizures and osteoarthritis, as well as pediatric patients with fragile X syndrome; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.